Cosmo Pharmaceuticals N.V (C43) — Strategic Asset Allocation Index
Cosmo Pharmaceuticals N.V (C43) has a Strategic Asset Allocation Index of 6.5% as of June 2022. Strategic assets (PP&E of €30.40 Million plus long-term investments of €-) total €30.40 Million, measured against net assets of €469.22 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check asset resilience ratio of Cosmo Pharmaceuticals N.V to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
Cosmo Pharmaceuticals N.V Strategic Asset Allocation Index (2016–2021)
This chart shows how Cosmo Pharmaceuticals N.V's Strategic Asset Allocation Index has evolved across 6 annual periods from 2016 to 2021. As of June 2022, the index stands at 6.5%, representing strategic assets of €30.40 Million against net assets of €469.22 Million EUR. See C43 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for Cosmo Pharmaceuticals N.V (2016–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for Cosmo Pharmaceuticals N.V from 2016 to 2021, covering 6 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see how much is Cosmo Pharmaceuticals N.V worth.
| Year | SAAI | Strategic Assets (EUR) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 5.9% | €30.48 Million | €30.48 Million | €- | €512.68 Million | ▼ -1.4 pp |
| 2020 | 7.3% | €29.30 Million | €29.30 Million | €- | €400.12 Million | ▼ -0.3 pp |
| 2019 | 7.7% | €30.19 Million | €30.19 Million | €- | €393.73 Million | ▲ +1.2 pp |
| 2018 | 6.4% | €28.62 Million | €28.62 Million | €- | €444.85 Million | ▲ +0.0 pp |
| 2017 | 6.4% | €30.15 Million | €30.15 Million | €- | €470.12 Million | ▲ +1.4 pp |
| 2016 | 5.0% | €20.67 Million | €20.67 Million | €- | €415.56 Million | — |